Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What is dabrafenib mesylate msn patent issue?
When did risperdal constas patent expire published article?
When does guselkumab patent expire?
Complera manufacturer?
Guselkumab brand name?

Insulin degludec insulin aspart price?

The price of insulin degludec/insulin aspart (Ryzodeg) can vary based on several factors, including dosage, formulation, insurance coverage, and geographic location.

How much does Ryzodeg cost without insurance?


Without insurance, a prescription for Ryzodeg can range significantly. For example, a 5-pen pack of Ryzodeg 70/30 100 units/mL can cost approximately $800 to $900 [1]. The exact retail price will depend on the pharmacy.

Can I get a Ryzodeg discount or coupon?


Several programs and coupons are available to help reduce the out-of-pocket cost of Ryzodeg. Manufacturer savings cards and discount programs offered by pharmacies can lower the price for eligible individuals. These programs often have specific terms and conditions regarding coverage and eligibility [2].

What is the price of Ryzodeg with insurance?


Insurance coverage for Ryzodeg significantly impacts its cost. With commercial insurance, copays can range from $0 to $150 or more per prescription, depending on the specific plan and formulary. Medicare Part D plans may have different copay structures, often falling into specific tiers with associated costs [2].

When does the patent for insulin degludec expire?


The patent landscape for insulin degludeg is complex, involving multiple patents that expire at different times. According to DrugPatentWatch.com, the earliest U.S. patent for insulin degludec is set to expire in late 2027, with other related patents extending further into the future, potentially into the mid-2030s [3]. These patent expirations are critical for the potential introduction of generic or biosimilar versions, which could influence pricing.

What is insulin degludec/insulin aspart used for?


Insulin degludec/insulin aspart is a combination rapid-acting and long-acting insulin. It is used to improve glycemic control in adults and children aged one year and older with diabetes mellitus [4]. This combination is designed to cover both mealtime insulin needs and basal (long-acting) insulin requirements.



Other Questions About Insulin :

When will insulin patent expire? Insulin glargine formulation excipients glycerol? Insulin pen price? When does the insulin patent expire? Insulin types and brand names? Geropharm private company insulin revenue? Generic insulin glargine?

AI-Drug Label Prescribing Information Alignment Report

18
18%
Grade F

Unsafe

Not Aligned

Patient Risk: High

Summary

Multiple claims refer to insulin degludec/insulin aspart but the provided label excerpts are for different products (Insulin Lispro Protamine and Insulin Lispro Mix75/25). At least one claim is contradicted by the provided label (pediatric use).

Category Scores

Indication
20
Poor
SpecificPopulations
0
Poor

Accurate Statements

None supported by the provided label excerpts for insulin degludec/insulin aspart.
Provided label sections (1, 8.4, 11) do not mention insulin degludec/insulin aspart.

Unsupported Statements

Insulin degludec/insulin aspart is a combination of rapid-acting and long-acting insulin.
Not supported by the provided excerpts; they describe a mixture of 75% intermediate-acting insulin lispro protamine and 25% rapid-acting insulin lispro for Insulin Lispro Protamine and Insulin Lispro Mix75/25.
Insulin degludec/insulin aspart is used to improve glycemic control in adults with diabetes mellitus.
Not supported for insulin degludec/insulin aspart in the provided excerpts; the indication provided is for Insulin Lispro Protamine and Insulin Lispro Mix75/25.
Insulin degludec/insulin aspart is designed to cover mealtime insulin needs.
The provided excerpts do not describe mealtime coverage designations for insulin degludec/insulin aspart.
Insulin degludec/insulin aspart is designed to cover basal (long-acting) insulin requirements.
The provided excerpts do not describe basal/long-acting requirement coverage for insulin degludec/insulin aspart.

Contradictions

High

AI Statement
Insulin degludec/insulin aspart is used to improve glycemic control in children aged one year and older with diabetes mellitus.

Label Reference
Section 8.4 Pediatric Use: “Safety and effectiveness of Insulin Lispro Protamine and Insulin Lispro Mix75/25 in pediatric patients have not been established.”

Important Omissions

No label-aligned prescribing details (e.g., dosing, administration, contraindications, boxed warnings, warnings/precautions, monitoring, or storage) were evaluated because the response only contained five high-level claims and the provided excerpts do not cover these sections for insulin degludec/insulin aspart.
Importance: Moderate

Safety Assessment

Potential Patient Risk: High
A pediatric efficacy use claim (age ≥1 year) is contradicted by the provided label excerpt stating pediatric safety/effectiveness have not been established. Additional claims are not supported and appear to conflate different insulin products.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use Yes
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Claims specifically about insulin degludec/insulin aspart are not supported by the provided label excerpts and at least one is contradicted regarding pediatric use.

Suggested Improvement
Remove or revise all claims to match the exact FDA label for insulin degludec/insulin aspart. Do not state pediatric indications or efficacy if the label provided states pediatric safety/effectiveness have not been established.